Partial changes to the use of funds raised through new shares and new share subscription rights, and to the timing of expenditures. The allocation period for CBP501 Phase 3 clinical trial costs has been extended and preparations for initiating the Phase 3 trial in Europe are underway. The unallocated amount of 973.9 million yen will continue to be allocated to clinical expenses, and the final timing for operating fund expenditures has been changed to August 2026. Overall impact is stated to have no effect on performance.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"price_fetched_at":"","company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4575","jir_company_name":"CanBas Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2606\u2606","jir_publication_date":"2026-10-14","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/10\/4575-20261014-03.pdf","jir_short_summary":"Partial changes to the use of funds raised through new shares and new share subscription rights, and to the timing of expenditures. The allocation period for CBP501 Phase 3 clinical trial costs has been extended and preparations for initiating the Phase 3 trial in Europe are underway. The unallocated amount of 973.9 million yen will continue to be allocated to clinical expenses, and the final timing for operating fund expenditures has been changed to August 2026. Overall impact is stated to have no effect on performance.","jir_summary":"### Overview of Change in Use of Proceeds\nOf the uses of proceeds announced in May 2023, the Board of Directors resolved today to change the timing of expenditures for CBP501 Phase 3 clinical trial costs and operating funds. Due to a delay in approval to start the Phase 3 clinical trial in the United States, funds for CBP501 have been shifted to preparations to start the trial with the European regulator (EMA). As a result, unallocated portions originally scheduled for allocation will be allocated beyond September 2026. Operating funds exceeded the amounts originally scheduled for allocation from July 2023 to April 2024, and additional allocations have been made from May 2024 onward.\n\n### Impact and Outlook\nThe company discloses that this change will not affect current-period results. The plan is to allocate the unallocated amounts going forward, extending the expenditure end dates: (1) to August 2028 and (2) to August 2026, respectively. Funds from the 17th series of share subscription rights have already been allocated, and the difference between total funds raised and allocated funds, 973.9 million yen, remains unallocated.","jir_financial_highlights":"CBP501 Phase 3 clinical trial costs: 3,271.9 (2,298 million yen already allocated; 973.9 million yen unallocated to be allocated going forward)\nOperating funds (basic research expenses, selling, general and administrative expenses): 1,560 (Actual allocated amount is 1,560 million yen; additional allocation of 1,175 million yen (May 2024\u2013August 2026))\nTotal funds raised: 3,721.9 (Net proceeds (approximate))","jir_category":"","jir_hashtags":"#Canbas, #ChangeInUseOfProceeds","jir_key_figures":"3,271.9 million yen: CBP501 Phase 3 clinical trial costs\n1,560 million yen: Operating funds (allocated)\n3,721.9 million yen: Total funds raised (net proceeds approx.)","jir_meta_title":"CanBas Co., Ltd. Announces Change in Use of Proceeds\uff5cAllocation Extended Beyond September 2026","jir_meta_description":"CanBas Co., Ltd. announced an extension of the allocation timing for CBP501 Phase 3 clinical trial costs and will proceed with preparations to start the trial with the EMA in Europe. Unallocated amounts will be allocated going forward and additional allocations for operating funds will be made. No impact on performance is expected.","jir_og_title":"CanBas Co., Ltd. Announces Change in Use of Proceeds\uff5cAllocation Timing Postponed","jir_og_description":"CanBas Co., Ltd. changed the timing of expenditures for clinical costs and operating funds, progressing preparations for a clinical trial start in Europe and continuing to allocate unallocated funds. No impact on results.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":58229,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"disclosure_update","footnotes":""},"sector":[],"importance":[],"class_list":["post-130830","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n